Startups & Business News
The world of pharmaceutical innovation just took a giant leap—literally—beyond Earth’s boundaries. Varda Space Industries has secured a staggering $187 million in Series C funding, a move that’s set to accelerate the development of drugs manufactured in the unique environment of space. This investment, led by Natural Capital and Shrug Capital with support from notable names like Peter Thiel and Founders Fund, brings Varda’s total capital raised to $329 million.
Why manufacture drugs in space?
The answer lies in the microgravity environment of low Earth orbit. On Earth, gravity can cause crystallization defects in drugs—especially complex biologics like monoclonal antibodies—impacting their bioavailability and effectiveness. In space, however, molecules float freely, enabling the formation of uniform crystals that can stabilize otherwise unstable drug forms and potentially enhance their therapeutic value.
Varda’s journey isn’t just theoretical
In 2023, the company’s W-1 mission successfully grew crystals of the anti-HIV drug ritonavir in orbit and returned them to Earth with their structure intact—a feat that had eluded researchers in terrestrial labs. This proof-of-concept demonstrated that space-based drug manufacturing could unlock new forms of medicines that are more effective and stable.
With the new funding, Varda is scaling up its operations.
The company has expanded its laboratory footprint in El Segundo, California, opening a 10,000-square-foot facility dedicated to advancing the crystallization of biologics and other pharmaceuticals. This lab will allow Varda’s team of structural biologists and crystallization experts to identify the most promising drug candidates for space-based production and refine the processes required for orbital manufacturing.
Varda isn’t stopping at drug development
Its orbital laboratories—the first of their kind outside the International Space Station—are also serving as hypersonic testbeds for government partners, including the U.S. Air Force and NASA, to test new technologies under real-world reentry conditions.
As the company prepares for additional missions—having already completed three successful launch-and-return operations with more on the horizon—Varda’s vision is clear: to make space the next frontier for pharmaceutical manufacturing, solving some of the industry’s toughest challenges and opening the door to life-changing medicines that would be impossible to create on Earth
Key Highlights
$187 Million Series C Funding:
Varda Space Industries has closed a major funding round, bringing its total capital raised to $329 million.Microgravity-Driven Innovation:
The company leverages the unique environment of space to develop pharmaceuticals with improved bioavailability and stability.Successful Space Mission:
Varda’s W-1 mission grew and returned high-quality crystals of the anti-HIV drug ritonavir, proving the viability of space-based drug manufacturing.Expansion of R&D Facilities:
Varda has launched a new 10,000-square-foot laboratory in El Segundo, California, dedicated to advancing space-enabled pharmaceutical research.Strategic Partnerships:
The funding round included support from leading investors and will help Varda collaborate with government agencies like NASA and the U.S. Air Force.Pioneering Orbital Labs:
Varda operates the first commercial orbital laboratories outside the ISS, supporting both pharmaceutical and hypersonic technology research.Future Missions Planned:
With three successful missions completed, Varda is preparing for additional launches to further expand its space-based drug development capabilities.
These highlights underscore Varda Space’s role in redefining the future of pharmaceutical innovation by harnessing the power of space.
futureTEKnow
Editorial Team
futureTEKnow is a leading source for Technology, Startups, and Business News, spotlighting the most innovative companies and breakthrough trends in emerging tech sectors like Artificial Intelligence (AI), Robotics, and the Space Industry.
Discover the companies and startups shaping tomorrow — explore the future of technology today.
Trending Companies
Latest Articles
China’s Noetix Robotics Raises Nearly $140M Series B to Scale Humanoid Robots
Noetix Robotics, a Beijing-based humanoid robotics startup, has closed a near-$140M Series B round to ramp up mass production and
Delphyr Raises €1.75M to Cut Healthcare Admin Work With AI Agents
Delphyr, a Dutch healthtech startup, has secured €1.75M to grow its AI agents that automate clinical documentation and admin work
Dwelly Raises $93M to Supercharge AI-Powered UK Rentals Roll-Up
London startup Dwelly just landed $93M to snap up UK rental agencies and inject AI smarts. Founders from Uber and
Encord Raises $60M Series C: Fueling Physical AI Data Wave
Encord just landed $60M in Series C funding to supercharge data tools for physical AI. Founders Eric Landau and Ulrik
Foodforecast Raises €8M Series A to Slash Ultra-Fresh Food Waste with AI
Foodforecast, a Cologne AI foodtech firm, just scored €8M in Series A funding led by SHIFT Invest. Their tools predict
AI-Driven Operational Excellence: How Leaders Scale Ownership, Discipline, and Continuous Improvement in 2026
In 2026, AI scales operational excellence fundamentals—clear ownership, disciplined execution, and continuous improvement—letting leaders focus on outcomes while systems handle
VoiceLine raises €10M to scale voice AI for enterprise frontline teams
Munich-based VoiceLine has closed a €10M Series A round to grow its voice AI platform for frontline sales and service
AI-Driven Logistics & Distribution Transformation: From Insight to Scalable Impact
AI is redefining logistics transformation—from network design to real-time execution. This article explores how data-driven insight, intelligent automation, and scalable
Hai Robotics Hong Kong IPO: From Startup Funding to Warehouse Robot Leader
Shenzhen’s Hai Robotics, pioneer in ACR warehouse robots, files for HK IPO after raising over $500M in funding rounds led
AI-Enabled Process Engineering & Continuous Improvement: Designing Systems That Learn
Explore how AI transforms process engineering and continuous improvement into self-learning systems. This article explains how organizations can design operations
Ouster Acquires StereoLabs: Unified Physical AI Sensing Platform Launches
Ouster’s $35M StereoLabs acquisition fuses lidar and ZED cameras into end-to-end Physical AI sensing. Founders Cecile Schmollgruber and team drive
Bretton AI Lands $75M Series B Funding to Scale AI Agents for Financial Crime and AML/KYC Compliance
Bretton AI’s $75M Series B modernizes AML KYC compliance via AI agents, slashing staffing costs for banks and fintechs like
futureTEKnow is focused on identifying and promoting creators, disruptors and innovators, and serving as a vital resource for those interested in the latest advancements in technology.
© 2026 All Rights Reserved.